WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsNasdaq Inc (NDAQ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 442% more annual revenue ($28.43B vs $5.25B). NDAQ leads profitability with a 34.1% profit margin vs 4.1%. NDAQ trades at a lower P/E of 28.0x. NDAQ earns a higher WallStSmart Score of 69/100 (B-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

NDAQ

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.5Value: 10.0Quality: 6.5
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.67

$24.25 discount

UndervaluedFair: $66.92Overvalued
NDAQUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$144.61

Current Price

$83.74

$60.87 discount

UndervaluedFair: $144.61Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

NDAQ3 strengths · Avg: 9.3/10
Profit MarginProfitability
34.1%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
47.6%10/10

Strong operational efficiency at 47.6%

EPS GrowthGrowth
47.6%8/10

Earnings expanding 47.6% YoY

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

NDAQ2 concerns · Avg: 4.0/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
28.0x4/10

Moderate valuation

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : NDAQ

The strongest argument for NDAQ centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 34.1% and operating margin at 47.6%. Revenue growth of 13.4% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : NDAQ

The primary concerns for NDAQ are PEG Ratio, P/E Ratio.

Key Dynamics to Monitor

MDLN profiles as a value stock while NDAQ is a mature play — different risk/reward profiles.

MDLN is growing revenue faster at 14.8% — sustainability is the question.

NDAQ generates stronger free cash flow (536M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NDAQ scores higher overall (69/100 vs 52/100), backed by strong 34.1% margins and 13.4% revenue growth. MDLN offers better value entry with a 32.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Nasdaq Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.

Visit Website →

Want to dig deeper into these stocks?